Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains statements which, to the extent they are not statements of historical fact, constitute “forward-looking statements.” Such forward-looking statements about our business and expectations within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), include statements relating to, among other things, our expectations regarding revenue recognition timing and amounts; business trends, earnings and other measures of financial performance; projected impact of foreign currency exchange rates and hedging activities; realizability of assets; future cash flow and uses of cash; future repurchases of common stock; future levels of indebtedness and capital spending; the working capital and liquidity outlook; critical accounting estimates; deductibility of goodwill; inflation; an ongoing litigation matter; and timing of delivery of pre-ordered IDEXX inVue Dx Cellular Analyzers in the U.S. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including, among other things, the adverse impact, and the duration, of macroeconomic events, conditions, and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty, inflationary pressures, severe weather and other natural conditions, and supply chain challenges on our business, results of operations, liquidity, financial condition, and stock price, as well as the other matters described under the headings “Business,” “Risk Factors,” “Legal Proceedings,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and “Quantitative and Qualitative Disclosure About Market Risk” in our 2023 Annual Report and in the corresponding sections of this Quarterly Report on Form 10-Q, and the Quarterly Reports on Form 10-Q for the quarters ended June 30, 2024, and March 31, 2024, as well as those described from time to time in our other periodic reports filed with the SEC.

Any forward-looking statements represent our estimates only as of the day this Quarterly Report on Form 10-Q was filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. From time to time, oral or written forward-looking statements may also be included in other materials released to the public, and they are subject to the risk and uncertainties described or cross-referenced in this section. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates or expectations change.

You should read the following discussion and analysis in conjunction with our 2023 Annual Report that includes additional information about us, our results of operations, our financial position, and our cash flows, and with our unaudited condensed consolidated financial statements and related notes included in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.

Our fiscal quarter ended on September 30. Unless otherwise stated, the analysis and discussion of our financial condition and results of operations below, including references to growth and organic growth and increases and decreases, are being compared to the equivalent prior-year periods.

Business Overview

We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing sectors. We also design, manufacture, and distribute point-of-care for the human medical diagnostics sector. Our primary products and services are:

• Point-of-care veterinary diagnostic products, comprising instruments, consumables, and rapid assay test kits;

• Veterinary reference laboratory diagnostic and consulting services;

• Practice management and diagnostic imaging systems and services used by veterinarians;

• Health monitoring, biological materials testing, and laboratory diagnostic instruments, and services used by the biomedical research community;

• Diagnostic, health-monitoring products for livestock, poultry, and dairy;

• Products that test water for certain microbiological contaminants; and

• Point-of-care electrolytes and blood gas analyzers.

Description of Business Segments. We operate primarily through three business segments: diagnostic and information management-based products and services for the companion animal veterinary industry, which we refer to as the Companion Animal Group (“CAG”); water quality products (“Water”); and diagnostic products and services for livestock and poultry

health and to ensure the quality and safety of milk and improve producer efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents our human medical diagnostic products business (“OPTI Medical”) with our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.

CAG develops, designs, manufactures, and distributes products and software, and performs services for veterinarians and the biomedical analytics sector, primarily related to diagnostics and information management. Water develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. LPD develops, designs, manufactures, and distributes diagnostic tests and related software and performs services that are used to manage the health status of livestock and poultry, to improve bovine reproductive efficiency, and to ensure the quality and safety of milk. OPTI Medical develops, designs, manufactures, and distributes human medical diagnostics products.

Currency and Other Items

Currency Impact. Refer to “Part I, Item 3. Quantitative and Qualitative Disclosures about Market Risk” included in this Quarterly Report on Form 10-Q for additional information regarding the impact of foreign currency exchange rates.

Other Items. Refer to “Part I, Item 1. Business - Patents and Licenses” and “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Annual Report for additional information regarding trends in companion animal healthcare, distributor purchasing and inventories, economic conditions, and patent expiration.

Critical Accounting Estimates and Assumptions

The discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The critical accounting policies and the significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024, are consistent with those discussed in our 2023 Annual Report in the section under the heading “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates and Assumptions.”

Recent Accounting Pronouncements

For more information regarding the impact that recent accounting standards and amendments will have on our consolidated financial statements, refer to Note 2 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.

Non-GAAP Financial Measures

The following revenue analysis and discussion focuses on organic revenue growth, and references in this analysis and discussion to “revenue,” “revenues,” or “revenue growth” are references to “organic revenue growth.” Organic revenue growth is a non-GAAP financial measure and represents the percentage change in revenue during the three and nine months ended September 30, 2024, as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Organic revenue growth should be considered in addition to, and not as a replacement for, or as a superior measure to, revenue growth reported in accordance with U.S. GAAP, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers.

We exclude from organic revenue growth the effect of changes in foreign currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility, and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates by applying the difference between the weighted average exchange rates during the current year period and the comparable prior-year period to foreign currency denominated revenues for the prior-year period.

We also exclude from organic revenue growth the effect of certain business acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period, and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.” In a business combination, if substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, we do not consider these assets to be a business. A typical acquisition that we do not consider a business is a customer list asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. We believe the efforts required to convert and retain these acquired customers are similar in nature to our existing customer base and therefore are included in organic revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions.

We also use Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio, and net debt to Adjusted EBITDA ratio in this Quarterly Report on Form 10-Q, all of which are non-GAAP financial measures that should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.

Results of Operations

Three Months Ended September 30, 2024, Compared to Three Months Ended September 30, 2023

Total Company. The following table presents total Company revenue by operating segment:

						For the Three Months Ended September 30,
Net Revenue (dollars in thousands)						2024						2023						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG						$	891,990					$	837,160					$	54,830					6.5		%				0.1		%				0.4		%				6.0		%
United States						604,170						573,830						30,340						5.3		%				—						0.6		%				4.6		%
International						287,820						263,330						24,490						9.3		%				0.3		%				—						9.0		%
Water						$	50,162					$	44,450					$	5,712					12.9		%				(0.3		%)				—						13.2		%
United States						26,671						22,804						3,867						17.0		%				—						—						17.0		%
International						23,491						21,646						1,845						8.5		%				(0.6		%)				—						9.2		%
LPD						$	28,992					$	29,747					$	(755)					(2.5		%)				(0.2		%)				—						(2.4		%)
United States						5,561						5,040						521						10.3		%				—						—						10.3		%
International						23,431						24,707						(1,276)						(5.2		%)				(0.2		%)				—						(5.0		%)
Other						$	4,399					$	4,170					$	229					5.5		%				—						—						5.5		%
Total Company						$	975,543					$	915,527					$	60,016					6.6		%				0.1		%				0.4		%				6.1		%
United States						638,058						603,046						35,012						5.8		%				—						0.6		%				5.2		%
International						337,485						312,481						25,004						8.0		%				0.2		%				—						7.8		%

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.

Total Company Revenue. The increase in organic revenue reflects growth in CAG Diagnostics recurring revenue, including benefits from higher realized prices and, to a lesser extent, increased volumes, supported by new business gains and sustained high customer retention rates offsetting constraints from macroeconomic and sector headwinds. Increases in our recurring veterinary software, services, and diagnostic imaging revenue, supported by higher volumes and price gains, also contributed to increased revenue. Higher revenue in our Water business was primarily due to higher realized prices and increased volume in the U.S. and, to a lesser extent, Europe. The decrease in LPD revenue was primarily due to lower testing levels in Asia Pacific, partially offset by higher volumes in North America, and benefits from higher realized prices. During the current quarter, the comparative impact of equivalent days, related to a shipping-day benefit, increased overall revenue growth by approximately 1%. Acquisitions increased revenue growth by 0.4%. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The following table presents total Company results of operations:

						For the Three Months Ended September 30,																								Change
Total Company - Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	975,543											$	915,527											$	60,016					6.6		%
Cost of revenue						379,505												367,545												11,960						3.3		%
Gross profit						596,038						61.1		%				547,982						59.9		%				48,056						8.8		%
Operating expenses:
Sales and marketing						146,281						15.0		%				135,698						14.8		%				10,583						7.8		%
General and administrative						91,887						9.4		%				89,034						9.7		%				2,853						3.2		%
Research and development						53,978						5.5		%				47,967						5.2		%				6,011						12.5		%
Total operating expenses						292,146						29.9		%				272,699						29.8		%				19,447						7.1		%
Income from operations						$	303,892					31.2		%				$	275,283					30.1		%				$	28,609					10.4		%

Gross Profit. Gross profit increased due to higher revenue and a 120 basis point increase in the gross profit margin. The increase in the gross profit margin reflected favorable business mix, lower instrument costs, recurring software and services gross margin gains, and the benefit from net price realization, offsetting inflationary cost impacts. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 20 basis points, including the impact of lower hedge gains during the current period compared to the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher travel, meeting, and personnel-related costs. General and administrative expense increased primarily due to higher information technology, outside services, and acquisition-related costs. Research and development expense increased primarily due to higher project costs. The change in foreign currency exchange rates decreased operating expense growth by approximately 1.0%.

Companion Animal Group

The following table presents revenue by product and service category for CAG:

						For the Three Months Ended September 30,
Net Revenue (dollars in thousands)						2024						2023						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG Diagnostics recurring revenue:						$	783,443					$	733,958					$	49,485					6.7		%				0.1		%				—						6.7		%
IDEXX VetLab consumables						329,128						296,042						33,086						11.2		%				0.1		%				—						11.1		%
Rapid assay products						92,774						87,562						5,212						6.0		%				(0.2		%)				—						6.2		%
Reference laboratory diagnostic and consulting services						328,383						320,294						8,089						2.5		%				0.1		%				—						2.4		%
CAG diagnostics services and accessories						33,158						30,060						3,098						10.3		%				0.1		%				—						10.2		%
CAG Diagnostics capital - instruments						$	29,528					$	32,254					$	(2,726)					(8.4		%)				0.3		%				—						(8.7		%)
Veterinary software, services and diagnostic imaging systems						$	79,019					$	70,948					$	8,071					11.4		%				0.1		%				5.2		%				6.1		%
Recurring revenue						64,644						54,607						10,037						18.4		%				0.1		%				6.8		%				11.5		%
Systems and hardware						14,375						16,341						(1,966)						(12.0		%)				—						—						(12.0		%)
Net CAG revenue						$	891,990					$	837,160					$	54,830					6.5		%				0.1		%				0.4		%				6.0		%

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding.

CAG Diagnostics Recurring Revenue. The increase in CAG Diagnostics recurring revenue was primarily due to higher realized prices and, to a lesser extent, increased volumes supported by new business gains and sustained high customer retention rates, offsetting constraints from macroeconomic and sector headwinds. The comparative impact of equivalent days, related to a shipping-day benefit in the current quarter, increased revenue growth by approximately 1%. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The increase in IDEXX VetLab consumables revenue was primarily due to higher price realization and, to a lesser extent, volume increases, supported by the expansion of our installed base of instruments and our expanded menu of available tests, and a shipping-day benefit in the current quarter. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The increase in rapid assay revenue resulted primarily from higher price realization and, to a lesser extent, a shipping-day benefit in the current quarter, partially offset by lower volumes. The change in foreign currency exchange rates decreased revenue growth by 0.2%.

The increase in reference laboratory diagnostic and consulting services revenue was due to higher global price realization and higher testing volumes, primarily in the U.S., and, to a lesser extent, in Asia Pacific and Europe. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The increase in CAG Diagnostics services and accessories revenue was primarily a result of the 10% growth in our active installed base of premium instruments. The change in foreign currency exchange rates increased revenue growth by 0.1%.

CAG Diagnostics Capital – Instrument Revenue. The decrease in instrument revenue was primarily due to lower premium instruments placements and, to a lesser extent, program effects on pricing. The change in foreign currency exchange rates increased revenue growth by 0.3%. Instrument revenue does not include our IDEXX inVue DxTM Cellular Analyzer pre-orders, which will be recognized in revenue when the instruments are delivered, which is anticipated to begin in North America during the fourth quarter of 2024.

Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in revenue was primarily due to higher recurring revenue from subscriptions and support revenue from an expanded SaaS installed base, and higher realized prices. The decrease in our systems and hardware revenue was due to lower system, accessories, and hardware sales. Acquisitions increased revenue growth by 5.2%. The change in foreign currency exchange rates increased revenue growth by 0.1%.

The following table presents the CAG segment results of operations:

						For the Three Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	891,990											$	837,160											$	54,830					6.5		%
Cost of revenue						347,529												337,869												9,660						2.9		%
Gross profit						544,461						61.0		%				499,291						59.6		%				45,170						9.0		%
Operating expenses:
Sales and marketing						132,848						14.9		%				123,657						14.8		%				9,191						7.4		%
General and administrative						84,611						9.5		%				78,770						9.4		%				5,841						7.4		%
Research and development						49,920						5.6		%				43,506						5.2		%				6,414						14.7		%
Total operating expenses						267,379						30.0		%				245,933						29.4		%				21,446						8.7		%
Income from operations						$	277,082					31.1		%				$	253,358					30.3		%				$	23,724					9.4		%

Gross Profit. Gross profit increased due to higher revenue and a 140 basis point increase in the gross profit margin. The increase in the gross profit margin reflected favorable business mix, lower instrument costs, recurring software and services gross margin gains, and the benefit from net price realization, offsetting inflationary cost impacts. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 10 basis points, including the impact of lower hedge gains during the current period compared to the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher travel, meeting, and personnel-related costs. General and administrative expense increased primarily due to higher information technology and outside services, as well as higher acquisition-related costs. Research and development expense increased primarily due to project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Water

The following table presents the Water segment results of operations:

						For the Three Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	50,162											$	44,450											$	5,712					12.9		%
Cost of revenue						15,407												13,416												1,991						14.8		%
Gross profit						34,755						69.3		%				31,034						69.8		%				3,721						12.0		%
Operating expenses:
Sales and marketing						5,936						11.8		%				5,345						12.0		%				591						11.1		%
General and administrative						3,903						7.8		%				4,125						9.3		%				(222)						(5.4		%)
Research and development						1,308						2.6		%				1,236						2.8		%				72						5.8		%
Total operating expenses						11,147						22.2		%				10,706						24.1		%				441						4.1		%
Income from operations						$	23,608					47.1		%				$	20,328					45.7		%				$	3,280					16.1		%

Revenue. The increase in revenue was due to higher realized prices and higher volumes. The increase in volumes in the U.S. and, to a lesser extent, Europe, was primarily from our Colilert test products and related accessories used in coliform and E. coli testing. The change in foreign currency exchange rates decreased revenue by approximately 0.3%.

Gross Profit. Gross profit increased due to higher revenue, partially offset by a 50 basis point decrease in the gross profit margin. The decrease in the gross profit margin was primarily due to higher product costs, partially offset by higher realized prices. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 50 basis points, including the impact of hedge losses during the current period compared to hedge gains in the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs and marketing initiatives. General and administrative expense decreased primarily due to lower bad debt expense. Research and development expense increased primarily due to higher personnel-related cost. The change in foreign currency exchange rates decreased operating expense growth by less than 1.0%.

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

						For the Three Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	28,992											$	29,747											$	(755)					(2.5		%)
Cost of revenue						14,365												13,911												454						3.3		%
Gross profit						14,627						50.5		%				15,836						53.2		%				(1,209)						(7.6		%)
Operating expenses:
Sales and marketing						7,210						24.9		%				6,253						21.0		%				957						15.3		%
General and administrative						3,933						13.6		%				4,199						14.1		%				(266)						(6.3		%)
Research and development						2,595						9.0		%				2,979						10.0		%				(384)						(12.9		%)
Total operating expenses						13,738						47.4		%				13,431						45.2		%				307						2.3		%
Income from operations						$	889					3.1		%				$	2,405					8.1		%				$	(1,516)					(63.0		%)

Revenue. The decrease in revenue was primarily due to lower testing levels in Asia Pacific, partially offset by higher volumes in North America and benefits from higher realized prices. The change in foreign currency exchange rates decreased revenue growth by 0.2%.

Gross Profit. The decrease in gross profit was primarily due to a 270 basis point decrease in the gross profit margin and lower revenue. The decrease in the gross profit margin was primarily due to higher product and distribution costs, partially offset by higher realized prices. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 70 basis points, including the impact of lower hedge gains during the current period compared to the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense decreased primarily due to lower bad debt expense. Research and development expense decreased primarily due to lower personnel-related and project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Other

The following table presents the Other results of operations:

						For the Three Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	4,399											$	4,170											$	229					5.5		%
Cost of revenue						2,204												2,349												(145)						(6.2		%)
Gross profit						2,195						49.9		%				1,821						43.7		%				374						20.5		%
Operating expenses:
Sales and marketing						287						6.5		%				443						10.6		%				(156)						(35.2		%)
General and administrative						(560)						(12.7		%)				1,940						46.5		%				(2,500)						(128.9		%)
Research and development						155						3.5		%				246						5.9		%				(91)						(37.0		%)
Total operating expenses						(118)						(2.7		%)				2,629						63.0		%				(2,747)						(104.5		%)
Income from operations						$	2,313					52.6		%				$	(808)					(19.4		%)				$	3,121					(386.3		%)

Revenue. The increase in revenue was primarily due to higher realized prices of our OPTI Medical consumables, partially offset by lower consumables volumes.

Gross Profit. Gross profit increased primarily due to a 620 basis point increase in the gross profit margin. The increase in the gross profit margin was largely due to higher realized prices. The change in foreign currency exchange rates did not have a significant impact on the gross profit margin.

Operating Expenses. Sales and marketing expense decreased due to lower personnel-related costs. General and administrative expense decreased primarily due to foreign exchange gains on settlements of foreign currency denominated transactions compared to losses in the prior period. Foreign exchange gains and losses on settlements for all operating segments are reported within Other. Research and development expense decreased due to lower activities that were not attributable to our three primary business segments.

Non-Operating Items

Interest Expense and Income. Interest expense was $7.7 million for the three months ended September 30, 2024, as compared to $8.6 million for the same period during the prior year. The decrease in interest expense was primarily due to lower average debt levels and lower interest rates. Interest income was $2.7 million for the three months ended September 30, 2024, compared to $1.3 million for the same period during the prior year. This increase in interest income is primarily due to the increase in money market investments, as compared to the same period during the prior year.

Provision for Income Taxes. Our effective income tax rate was 22.1% for the three months ended September 30, 2024, compared to 20.8% for the three months ended September 30, 2023. The increase in our effective tax rate was primarily due to lower tax benefits related to share-based compensation, partially offset by the tax impact of differences in geographical income mix.

Results of Operations

Nine Months Ended September 30, 2024, Compared to Nine Months Ended September 30, 2023

Total Company. The following table presents total Company revenue by operating segment:

						For the Nine Months Ended September 30,
Net Revenue (dollars in thousands)						2024						2023						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG						$	2,703,573					$	2,531,091					$	172,482					6.8		%				(0.2		%)				0.4		%				6.7		%
United States						1,835,049						1,732,752						102,297						5.9		%				—						0.5		%				5.4		%
International						868,524						798,339						70,185						8.8		%				(0.6		%)				—						9.4		%
Water						$	139,959					$	126,362					$	13,597					10.8		%				(0.4		%)				—						11.1		%
United States						73,331						63,932						9,399						14.7		%				—						—						14.7		%
International						66,628						62,430						4,198						6.7		%				(0.7		%)				—						7.5		%
LPD						$	87,503					$	88,866					$	(1,363)					(1.5		%)				(0.6		%)				—						(0.9		%)
United States						15,840						14,005						1,835						13.1		%				—						—						13.1		%
International						71,663						74,861						(3,198)						(4.3		%)				(0.7		%)				—						(3.6		%)
Other						$	12,181					$	13,033					$	(852)					(6.5		%)				—						—						(6.5		%)
Total Company						$	2,943,216					$	2,759,352					$	183,864					6.7		%				(0.2		%)				0.3		%				6.6		%
United States						1,929,213						1,815,066						114,147						6.3		%				—						0.5		%				5.8		%
International						1,014,003						944,286						69,717						7.4		%				(0.6		%)				—						8.0		%

(1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.

Total Company Revenue. The increase in organic revenue reflects growth in CAG Diagnostics recurring revenue, including benefits from higher realized prices and, to a lesser extent, increased volumes, supported by new business gains and sustained high customer retention rates offsetting constraints from macroeconomic and sector headwinds. Higher volumes and price gains in recurring veterinary software, services, and diagnostic imaging also contributed to increased revenue, supported by demand for subscription-based software. Higher revenue in our Water business was primarily due to the benefit of price increases and increased volume in the U.S. and Europe. The decrease in LPD revenue was primarily due to lower testing levels in Asia Pacific, partially offset by higher realized prices and volume growth in the U.S. and Europe. The decrease in Other revenue was primarily due to lower volumes of our OPTI Medical instruments and consumables. Acquisitions increased revenue growth by 0.3%. The change in foreign currency exchange rates decreased revenue growth by 0.2%.

The following table presents total Company results of operations:

						For the Nine Months Ended September 30,																								Change
Total Company - Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	2,943,216											$	2,759,352											$	183,864					6.7		%
Cost of revenue						1,134,949												1,095,549												39,400						3.6		%
Gross profit						1,808,267						61.4		%				1,663,803						60.3		%				144,464						8.7		%
Operating expenses:
Sales and marketing						438,399						14.9		%				424,034						15.4		%				14,365						3.4		%
General and administrative						341,154						11.6		%				248,804						9.0		%				92,350						37.1		%
Research and development						162,063						5.5		%				139,139						5.0		%				22,924						16.5		%
Total operating expenses						941,616						32.0		%				811,977						29.4		%				129,639						16.0		%
Income from operations						$	866,651					29.4		%				$	851,826					30.9		%				$	14,825					1.7		%

Gross Profit. Gross profit increased due to higher revenue and a 110 basis point increase in the gross profit margin. The increase in the gross profit margin reflected favorable business mix, lower instrument costs, recurring software and services gross margin gains, and the benefit from net price realization, offsetting inflationary cost impacts. The change in foreign currency exchange rates on the gross profit margin was not significant.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related, meeting, and travel costs. General and administrative expense increased primarily due to a $61.5 million expense related to an ongoing litigation matter, the comparison to the prior year benefit of a $16.0 million customer contract resolution gain, higher information technology and outside services, and acquisition-related costs. Research and development expense increased primarily due to higher project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Companion Animal Group

The following table presents revenue by product and service category for CAG:

						For the Nine Months Ended September 30,
Net Revenue (dollars in thousands)						2024						2023						Dollar Change						Reported Revenue Growth (1)						Percentage Change from Currency						Percentage Change from Acquisitions						Organic Revenue Growth (1)
CAG Diagnostics recurring revenue:						$	2,372,041					$	2,223,336					$	148,705					6.7		%				(0.2		%)				—						6.9		%
IDEXX VetLab consumables						971,405						890,891						80,514						9.0		%				(0.3		%)				—						9.3		%
Rapid assay products						282,379						266,934						15,445						5.8		%				(0.2		%)				—						6.0		%
Reference laboratory diagnostic and consulting services						1,020,094						973,580						46,514						4.8		%				(0.1		%)				—						4.9		%
CAG diagnostics services and accessories						98,163						91,931						6,232						6.8		%				(0.4		%)				—						7.2		%
CAG Diagnostics capital - instruments						$	98,912					$	99,452					$	(540)					(0.5		%)				(0.4		%)				—						(0.1		%)
Veterinary software, services and diagnostic imaging systems:						$	232,620					$	208,303					$	24,317					11.7		%				—						4.4		%				7.3		%
Recurring revenue						187,461						160,039						27,422						17.1		%				—						5.7		%				11.5		%
Systems and hardware						45,159						48,264						(3,105)						(6.4		%)				(0.1		%)				—						(6.4		%)
Net CAG revenue						$	2,703,573					$	2,531,091					$	172,482					6.8		%				(0.2		%)				0.4		%				6.7		%

(1) Reported revenue growth and organic revenue growth may not recalculate due to rounding.

CAG Diagnostics Recurring Revenue. The increase in CAG Diagnostics recurring revenue was primarily due to higher realized prices and, to a lesser extent, increased volumes, supported by new business gains and sustained high customer retention rates, offsetting constraints from macroeconomic and sector headwinds. The impact in foreign currency exchange rates decreased CAG Diagnostics recurring revenue growth by 0.2%.

The increase in IDEXX VetLab consumables revenue was primarily due to higher price realization and, to a lesser extent, volume increases, supported by the expansion of our installed base of instruments and our expanded menu of available tests. The change in foreign currency exchange rates decreased revenue growth by 0.3%.

The increase in rapid assay revenue resulted primarily from higher price realization, partially offset by lower volumes. The change in foreign currency exchange rates decreased revenue growth by 0.2%.

The increase in reference laboratory diagnostic and consulting services revenue was due to higher global price realization and higher testing volumes, primarily in the U.S. and, to a lesser extent, Asia Pacific and Europe. The change in foreign currency exchange rates decreased revenue growth by 0.1%.

The increase in CAG Diagnostics services and accessories revenue was primarily a result of the 10% growth in our active installed base of premium instruments. The change in foreign currency exchange rates decreased revenue growth by 0.4%.

CAG Diagnostics Capital – Instrument Revenue. The decrease in instrument revenue was primarily due to program effects on pricing, largely offset by higher premium instrument placements. The change in foreign currency exchange rates decreased revenue growth by 0.4%.

Veterinary Software, Services and Diagnostic Imaging Systems Revenue. The increase in revenue was primarily due to higher realized prices and higher recurring revenue from subscription and support revenue from an expanded SaaS installed base. The decrease in our systems and hardware revenue was due to lower hardware sales associated with new software

placements, which are primarily cloud-based, and lower accessories sales. The change in foreign currency exchange rates was not significant to revenue growth. Acquisitions increased revenue growth by 4.4%.

The following table presents the CAG segment results of operations:

						For the Nine Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	2,703,573											$	2,531,091											$	172,482					6.8		%
Cost of revenue						1,043,805												1,007,334												36,471						3.6		%
Gross profit						1,659,768						61.4		%				1,523,757						60.2		%				136,011						8.9		%
Operating expenses:
Sales and marketing						399,186						14.8		%				387,695						15.3		%				11,491						3.0		%
General and administrative						313,442						11.6		%				219,758						8.7		%				93,684						42.6		%
Research and development						148,812						5.5		%				125,687						5.0		%				23,125						18.4		%
Total operating expenses						861,440						31.9		%				733,140						29.0		%				128,300						17.5		%
Income from operations						$	798,328					29.5		%				$	790,617					31.2		%				$	7,711					1.0		%

Gross Profit. Gross profit increased due to higher revenue and a 120 basis point increase in the gross profit margin. The increase in the gross profit margin reflected favorable business mix, lower instrument costs, recurring software and services gross margin gains, and the benefit from net price realization, offsetting inflationary cost impacts. The change in foreign currency exchange rates on the gross profit margin was not significant.

Operating Expenses. Sales and marketing expense increased primarily due to personnel-related, meeting, and travel costs. General and administrative expense increased primarily due to a $61.5 million expense related to an ongoing litigation matter, the comparison to the prior year benefit of a $16.0 million customer contract resolution gain, and higher information technology and outside services, as well as higher acquisition-related costs. Research and development expense increased primarily due to project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Water

The following table presents the Water segment results of operations:

						For the Nine Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	139,959											$	126,362											$	13,597					10.8		%
Cost of revenue						42,633												37,741												4,892						13.0		%
Gross profit						97,326						69.5		%				88,621						70.1		%				8,705						9.8		%
Operating expenses:
Sales and marketing						17,423						12.4		%				15,814						12.5		%				1,609						10.2		%
General and administrative						12,534						9.0		%				12,054						9.5		%				480						4.0		%
Research and development						3,827						2.7		%				3,634						2.9		%				193						5.3		%
Total operating expenses						33,784						24.1		%				31,502						24.9		%				2,282						7.2		%
Income from operations						$	63,542					45.4		%				$	57,119					45.2		%				$	6,423					11.2		%

Revenue. The increase in revenue was due to higher realized prices and higher volumes. The increase in volumes in the U.S. and Europe was primarily from our Colilert test products and related accessories used in coliform and E. coli testing. The change in foreign currency exchange rates decreased revenue growth by 0.4%.

Gross Profit. Gross profit increased due to higher revenue, partially offset by a 60 basis point decrease in the gross profit margin. The decrease in the gross profit margin was primarily due to higher product costs, partially offset by higher realized prices. The overall change in foreign currency exchange rates decreased the gross profit margin by approximately 10 basis points, including the impact of lower hedge gains during the current period compared to the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs and marketing initiatives. General and administrative expense increased primarily due to higher personnel-related costs and an increase in bad debt expense. Research and development expense increased primarily due to higher outside service costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Livestock, Poultry and Dairy

The following table presents the LPD segment results of operations:

						For the Nine Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	87,503											$	88,866											$	(1,363)					(1.5		%)
Cost of revenue						42,084												41,891												193						0.5		%
Gross profit						45,419						51.9		%				46,975						52.9		%				(1,556)						(3.3		%)
Operating expenses:
Sales and marketing						20,937						23.9		%				19,153						21.6		%				1,784						9.3		%
General and administrative						12,420						14.2		%				13,075						14.7		%				(655)						(5.0		%)
Research and development						8,808						10.1		%				9,083						10.2		%				(275)						(3.0		%)
Total operating expenses						42,165						48.2		%				41,311						46.5		%				854						2.1		%
Income from operations						$	3,254					3.7		%				$	5,664					6.4		%				$	(2,410)					(42.5		%)

Revenue. The decrease in revenue was primarily due to lower testing levels in Asia Pacific, partially offset by higher realized prices and volumes growth in the U.S. and Europe. The change in foreign currency exchange rates decreased revenue growth by 0.6%.

Gross Profit. The decrease in gross profit was primarily due to a 100 basis point decrease in the gross profit margin and lower revenue. The decrease in the gross profit margin was primarily due to higher product and distribution costs and unfavorable business mix, partially offset by higher realized prices. The overall change in foreign currency exchange rates increased the gross profit margin by approximately 20 basis points, including the impact of hedge gains during the current period compared to hedge losses during the prior period.

Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense decreased primarily due to lower bad debt expense and personnel-related costs. Research and development expense decreased primarily due to lower project costs. The change in foreign currency exchange rates was not significant to operating expense growth.

Other

The following table presents the Other results of operations:

						For the Nine Months Ended September 30,																								Change
Results of Operations (dollars in thousands)						2024						Percent of Revenue						2023						Percent of Revenue						Amount						Percentage
Revenues						$	12,181											$	13,033											$	(852)					(6.5		%)
Cost of revenue						6,427												8,583												(2,156)						(25.1		%)
Gross profit						5,754						47.2		%				4,450						34.1		%				1,304						29.3		%
Operating expenses:
Sales and marketing						853						7.0		%				1,372						10.5		%				(519)						(37.8		%)
General and administrative						2,758						22.6		%				3,917						30.1		%				(1,159)						(29.6		%)
Research and development						616						5.1		%				735						5.6		%				(119)						(16.2		%)
Total operating expenses						4,227						34.7		%				6,024						46.2		%				(1,797)						(29.8		%)
Income from operations						$	1,527					12.5		%				$	(1,574)					(12.1		%)				$	3,101					(197.0		%)

Revenue. The decrease in revenue was primarily due to lower volumes of our OPTI Medical instruments and consumables, partially offset by higher realized prices.

Gross Profit. Gross profit increased due to a 1,310 basis point increase in the gross profit margin, which offset the impact from lower revenue. The increase in the gross profit margin was largely due to higher realized prices. The change in foreign currency exchange rates did not have a significant impact on the gross profit margin.

Operating Expenses. Sales and marketing expense decreased due to lower compensation costs. General and administrative expense decreased primarily due to lower foreign exchange losses on settlements of foreign currency denominated transactions compared to the prior period. Foreign exchange gains and losses on settlements for all operating segments are reported within Other. Research and development expense decreased due to lower activities that were not attributable to our three primary business segments.

Non-Operating Items

Interest Expense and Income. Interest expense was $23.7 million for the nine months ended September 30, 2024, as compared to $32.3 million for the same period during the prior year. The decrease in interest expense was primarily due to lower average debt levels and, to a lesser extent, lower interest rates. Interest income was $10.5 million for the nine months ended September 30, 2024, compared to $2.0 million for the same period during the prior year. This increase in interest income is primarily due to the increase in money market investments, as compared to the same period during the prior year.

Provision for Income Taxes. Our effective income tax rate was 21.3% for the nine months ended September 30, 2024, compared to 20.8% for the nine months ended September 30, 2023. The increase in our effective tax rate was primarily due to lower tax benefits related to share-based compensation, partially offset by the tax impact of differences in geographical income mix.

Liquidity and Capital Resources

We fund the capital needs of our business through cash on hand, funds generated from operations, proceeds from long-term senior note financings, and amounts available under our Credit Facility. We generate cash primarily through the payments made by customers for our companion animal veterinary, livestock, poultry, dairy, and water products and services, consulting services, and other various systems and services. Our cash disbursements are primarily related to compensation and benefits for our employees, inventory and supplies, repurchases of our common stock, taxes, research and development, capital expenditures, rents, occupancy-related charges, interest expense, and business acquisitions. As of September 30, 2024, we had $308.6 million of cash and cash equivalents, compared to $453.9 million as of December 31, 2023. Working capital totaled $424.5 million as of September 30, 2024, compared to $543.7 million as of December 31, 2023. As of September 30, 2024, we had a remaining borrowing availability of $998.2 million under our $1.25 billion Credit Facility, with $250.0 million in outstanding borrowings under the Credit Facility. The general availability of funds under our Credit Facility is reduced by $1.8 million for outstanding letters of credit. We believe that, if necessary, we could obtain additional borrowings to fund our growth objectives. We further believe that current cash and cash equivalents, funds generated from operations, and committed borrowing availability will be sufficient to fund our operations, capital purchase requirements, and anticipated growth needs for the next twelve months. We believe that these resources, coupled with our ability, as needed, to obtain additional financing, will also be sufficient to fund our business as currently conducted for the foreseeable future. We may enter into new financing arrangements or refinance or retire existing debt in the future depending on market conditions. Should we require more capital in the U.S. than is generated by our operations, for example, to fund significant discretionary activities, we could elect to raise capital in the U.S. through the incurrence of debt or equity issuances, which we may not be able to complete on favorable terms or at all. In addition, these alternatives could result in increased interest expense or other dilution of our earnings.

We manage our worldwide cash requirements considering available funds among all of our subsidiaries. Our foreign cash and cash equivalents are generally available without restrictions to fund ordinary business operations outside the U.S.

The following table presents cash and cash equivalents held domestically and by our foreign subsidiaries:

Cash and cash equivalents (dollars in thousands)						September 30, 2024						December 31, 2023
U.S.						$	181,689					$	324,434
Foreign						126,947						129,498
Total						$	308,636					$	453,932
Total cash and cash equivalents held in U.S. dollars by our foreign subsidiaries						$	7,241					$	13,170

Of the $308.6 million of cash and cash equivalents held as of September 30, 2024, approximately $136.1 million was held as bank deposits at a diversified group of institutions, primarily systemically important banks, and $172.5 million was held in a U.S. government money market fund. As of December 31, 2023, of the $453.9 million of cash and cash equivalents held, $163.1 million was held as bank deposits at a diversified group of institutions, primarily systemically important banks, and $290.8 million was held in a U.S. government money market fund. Cash and cash equivalents as of September 30, 2024, included approximately $1.0 million in cash denominated in non-U.S. currencies held in a country with currency control restrictions, which limit our ability to transfer funds outside of the country in which they are held without incurring costs.

The following table presents additional key information concerning working capital:

			For the Three Months Ended
			September 30, 2024						June 30, 2024						March 31, 2024						December 31, 2023						September 30, 2023
Days sales outstanding (1)			48.9						47.3						45.7						46.1						45.6
Inventory turns (2)			1.3						1.4						1.3						1.3						1.3

(1) Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

(2) Inventory turns are calculated as the ratio of four times our inventory-related cost of revenue for the quarter, divided by the average inventory balances at the beginning and end of each quarter.

Sources and Uses of Cash

The following table presents cash provided (used):

						For the Nine Months Ended September 30,
(dollars in thousands)						2024						2023						Change
Net cash provided by operating activities						$	666,976					$	656,659					$	10,317
Net cash used by investing activities						(167,219)						(94,819)						(72,400)
Net cash used by financing activities						(645,291)						(340,152)						(305,139)
Net effect of changes in exchange rates on cash						238						(2,538)						2,776
Net change in cash and cash equivalents						$	(145,296)					$	219,150					$	(364,446)

Operating Activities. Cash provided by operating activities during the nine months ended September 30, 2024, increased $10.3 million, compared to the same period during the prior year, primarily due to higher net income, partially offset by higher income tax and annual employee incentive program payments during the current period. The following table presents cash flow impacts from changes in operating assets and liabilities:

						For the Nine Months Ended September 30,
(dollars in thousands)						2024						2023						Change
Accounts receivable						$	(56,087)					$	(54,557)					$	(1,530)
Inventories						(24,756)						(31,647)						6,891
Accounts payable						2,347						(6,799)						9,146
Deferred revenue						(735)						(3,347)						2,612
Other assets and liabilities						(45,272)						(17,902)						(27,370)
Total change in cash due to changes in operating assets and liabilities						$	(124,503)					$	(114,252)					$	(10,251)

Cash provided by changes in operating assets and liabilities during the nine months ended September 30, 2024, increased $10.3 million, compared to the same period during the prior year. The $27.4 million increase in cash used for other assets and liabilities was primarily due to higher annual cash taxes paid, compared to the same period in the prior year, higher annual employee incentive program payments during the current period, a net increase in consideration paid to customers and a $10.0 million royalty prepayment in the current year. Uses of cash were partially offset by higher non-cash operating expenses recorded as accrued liabilities, including a $61.5 million accrual charge related to an ongoing litigation matter recorded in the second quarter of 2024, and by a comparative benefit from the use of cash during the prior year for a $15.0 million milestone payment to license intellectual property.

We have historically experienced proportionally lower net cash flows from operating activities during the first quarter and proportionally higher cash flows from operating activities for the remainder of the year driven primarily by payments related to annual employee incentive programs in the first quarter following the year for which the bonuses were earned.

Investing Activities. Cash used by investing activities was $167.2 million during the nine months ended September 30, 2024, compared to $94.8 million for the same period during the prior year. The increase in cash used by investing activities was primarily due to the acquisition of a software business during the current year.

Our total capital expenditure outlook for 2024 is estimated to be approximately $160 million, which includes capital investments to support growth in manufacturing and operations facilities and in customer-facing software development.

Financing Activities. Cash used by financing activities was $645.3 million during the nine months ended September 30, 2024, compared to $340.2 million of cash used for the same period during the prior year. The increase in cash used was primarily due to $591.0 million of repurchases of our common stock during the current year, compared to $35.1 million of repurchases during the prior year, and due to the July 2024 repayment of our $75.0 million 2024 Series B Notes. This increase in cash used by financing was partially offset by no net borrowings or repayments under our Credit Facility during the current year, compared to repayments of $329.0 million under our Credit Facility during the prior year.

We believe that the repurchase of our common stock is a favorable means of returning value to our stockholders, and we also repurchase our stock to offset the dilutive effect of our share-based compensation programs. Repurchases of our common stock may vary depending upon the level of other investing and deployment activities, as well as share price and prevailing interest rates. Refer to Note 12 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q for additional information about our share repurchases.

As of September 30, 2024, we had $250.0 million in outstanding borrowings under the Credit Facility. The obligations under our Credit Facility may be accelerated upon the occurrence of an event of default under the Credit Facility, which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under the Employee Retirement Income Security Act of 1974 (“ERISA”), the failure to pay specified indebtedness, cross-acceleration to specified indebtedness, and a change of control default. The Credit Facility contains affirmative, negative, and financial covenants customary for financings of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, fundamental changes, investments, transactions with affiliates, and certain restrictive agreements. The financial covenant is a consolidated leverage ratio test.

We anticipate paying off the aggregate principal amounts of our €88.9 million 2025 Series C Notes, which will become due and payable on June 18, 2025, with available cash on hand at time of payment.

Should we elect to prepay any of our senior notes, such aggregate prepayment will include the applicable make-whole amount(s), as defined within the applicable Senior Note Agreements. Additionally, in the event of a change in control of the Company or upon the disposition of certain assets of the Company, the proceeds of which are not reinvested (as defined in the Senior Note Agreements), we may be required to prepay all or a portion of the senior notes. The obligations under the senior notes may be accelerated upon the occurrence of an event of default under the applicable Senior Note Agreements, each of which includes customary events of default including payment defaults, defaults in the performance of the affirmative, negative and financial covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency-related defaults, defaults relating to judgments, certain events related to employee pension benefit plans under ERISA, the failure to pay specified indebtedness, cross-acceleration to specified indebtedness, and a change of control default.

Effect of Currency Translation on Cash. The net effect of changes in foreign currency exchange rates is related to changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. These changes will fluctuate for each period presented as the value of the U.S. dollar relative to the value of foreign currencies changes. A currency’s value depends on many factors, including interest rates and the issuing governments’ debt levels and strength of economy.

Off-Balance Sheet Arrangements. We have no off-balance sheet arrangements or variable interest entities, except for letters of credit and third-party guarantees.

Financial Covenant. The sole financial covenant of our Credit Facility and Senior Note Agreements is a consolidated leverage ratio test that requires our ratio of debt to earnings before interest, taxes, depreciation and amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges (“Adjusted EBITDA”), as defined in the Senior Note Agreement and Credit Facility, not to exceed 3.5-to-1. As of September 30, 2024, we were in compliance with such covenant. The following details our consolidated leverage ratio calculation:

(dollars in thousands)			Twelve Months Ended
Trailing 12 Months Adjusted EBITDA:			September 30, 2024
Net income attributable to stockholders			$	866,239
Interest expense			32,972
Provision for income taxes			226,873
Depreciation and amortization			125,967
Acquisition-related expense			276
Share-based compensation expense			61,260
Extraordinary and other non-recurring non-cash charges			1,734
Adjusted EBITDA			$	1,315,321
Debt to Adjusted EBITDA Ratio:			September 30, 2024
Line of Credit			$	250,000
Current and long-term portions of long-term debt			623,898
Total debt			873,898
Acquisition-related contingent consideration payable			4,687
Deferred financing costs			249
Gross debt			$	878,834
Gross debt to Adjusted EBITDA ratio			0.67
Less: Cash and cash equivalents			$	308,636
Net debt			$	570,198
Net debt to Adjusted EBITDA ratio			0.43

Adjusted EBITDA, gross debt, net debt, gross debt to Adjusted EBITDA ratio, and net debt to Adjusted EBITDA ratio are non-GAAP financial measures which should be considered in addition to, and not as a replacement for, financial measures presented according to U.S. GAAP. Management believes that reporting these non-GAAP financial measures provides supplemental analysis to help investors further evaluate our business performance and available borrowing capacity under our Credit Facility.

Other Commitments, Contingencies and Guarantees

Significant commitments, contingencies, and guarantees as of September 30, 2024, are described in Note 16 to the unaudited condensed consolidated financial statements in “Part I. Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.

During the third quarter of 2024, we remitted our final payment of $21.8 million for the deemed repatriation tax imposed by the U.S. Tax Cut and Jobs Act of 2017.